Trial reportRevista da Associacao Medica Brasileira (1992)2026
Effect of adding indocyanine green to identifying sentinel lymph node in breast cancer patients after neoadjuvant chemotherapy.
Trial report in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of the study was to examine the effectiveness of adding indocyanine green fluorescence to the dual method, (Radioisotope+Isosulfanblue) for sentinel lymph node biopsy after neoadjuvant chemotherapy (on sentinel lymph nodes identification).
methodsThe 101 patients included in the study were randomized equally into each group. Dual method containing indocyanine green (group 1) or dual method alone (group 2) was used for sentinel lymph node mapping.
resultsThe sentinel lymph node identification rate was 86.9% in the dual method group and 94.6% in the triple method group. The detection rates of two or more sentinel lymph nodes were 82.6% in the dual group and 89.2% in the triple group. There was no statistically significant difference between both the groups (p>0.05).
conclusionIndocyanine green-based sentinel lymph node biopsy detection will bring a significant change in the management of patients in centers where there is no access to a nuclear medicine department. Nevertheless, multicenter studies with larger patient samples are needed to confirm our results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.